Follow-up Patients With End Stage Renal Disease Receiving Zemplar to Prevent and Treat Secondary Hyperparathyroidism

Mise à jour : Il y a 4 ans
Référence : NCT01081665

Femme et Homme

  • | Pays :
  • Greece
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The aim of this post-marketing observational study is to obtain further data on the long term use, safety and efficacy of Zemplar as it is prescribed in the normal clinical setting and according to the approved Summary of Product Characteristics for the treatment of secondary hyperparathyroidism in hemodialysis patients in Greece.


Critère d'inclusion

  • Chronic Kidney Failure ,Secondary hyperparathyroidism

Liens